open access

Vol 20, No 3 (2015)
Original research articles
Published online: 2015-05-01
Submitted: 2014-07-08
Get Citation

Tailor-made treatment combined with proton beam therapy for children with genitourinary/pelvic rhabdomyosarcoma

Hiroko Fukushima, Takashi Fukushima, Aiko Sakai, Ryoko Suzuki, Chie Kobayashi, Yoshiko Oshiro, Masashi Mizumoto, Noriko Hoshino, Chikashi Gotoh, Yasuhisa Urita, Hiroaki Komuro, Michio Kaneko, Noritoshi Sekido, Kouji Masumoto, Hideyuki Sakurai, Ryo Sumazaki
DOI: 10.1016/j.rpor.2014.12.003
·
Rep Pract Oncol Radiother 2015;20(3):217-222.

open access

Vol 20, No 3 (2015)
Original research articles
Published online: 2015-05-01
Submitted: 2014-07-08

Abstract

Background

Rhabdomyosarcoma (RMS) is one of the most common soft tissue sarcomas among children. Patients who developed genitourinary/pelvic rhabdomyosarcoma (GU/P-RMS) have a higher complication ratio and relatively poorer event free survival, with local therapy being very important. While proton beam therapy (PBT) is expected to reduce co-morbidity, especially for children, this lacks firm evidence and analysis. We analyzed GU/P-RMS children who had undergone multimodal therapy combined with PBT at a single institution.

Method

We retrospectively reviewed charts of children with GU/P-RMS treated from January 2007 to May 2013 at the University of Tsukuba Hospital who had undergone multimodal therapy with PBT.

Results

There were 5 children and their median age at diagnosis was 2.8 years (0.6–4.4 years). Primary sites were the bladder (2) and the prostate (3). All received neo-adjuvant chemotherapy and 3 underwent chemotherapy during PBT (Group Cx). All patients of Group Cx developed leukocytopenia (WBC <1000/μL). The median dose of PBT was 47.7[[ce:hsp sp="0.25"/]]GyE (41.4–50.4[[ce:hsp sp="0.25"/]]GyE). All patients survived by their last hospital visit (median, 36 months).

Conclusions

We analyzed multimodal treatment combined with PBT applied for GU/P-RMS. PBT was well tolerated and could be a plausible choice instead of photon therapy for this population.

Abstract

Background

Rhabdomyosarcoma (RMS) is one of the most common soft tissue sarcomas among children. Patients who developed genitourinary/pelvic rhabdomyosarcoma (GU/P-RMS) have a higher complication ratio and relatively poorer event free survival, with local therapy being very important. While proton beam therapy (PBT) is expected to reduce co-morbidity, especially for children, this lacks firm evidence and analysis. We analyzed GU/P-RMS children who had undergone multimodal therapy combined with PBT at a single institution.

Method

We retrospectively reviewed charts of children with GU/P-RMS treated from January 2007 to May 2013 at the University of Tsukuba Hospital who had undergone multimodal therapy with PBT.

Results

There were 5 children and their median age at diagnosis was 2.8 years (0.6–4.4 years). Primary sites were the bladder (2) and the prostate (3). All received neo-adjuvant chemotherapy and 3 underwent chemotherapy during PBT (Group Cx). All patients of Group Cx developed leukocytopenia (WBC <1000/μL). The median dose of PBT was 47.7[[ce:hsp sp="0.25"/]]GyE (41.4–50.4[[ce:hsp sp="0.25"/]]GyE). All patients survived by their last hospital visit (median, 36 months).

Conclusions

We analyzed multimodal treatment combined with PBT applied for GU/P-RMS. PBT was well tolerated and could be a plausible choice instead of photon therapy for this population.

Get Citation

Keywords

Rhabdomyosarcoma; Proton-beam therapy; Genitourinary/pelvic tumor; Childhood malignancy; Multimodal therapy

About this article
Title

Tailor-made treatment combined with proton beam therapy for children with genitourinary/pelvic rhabdomyosarcoma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 3 (2015)

Pages

217-222

Published online

2015-05-01

DOI

10.1016/j.rpor.2014.12.003

Bibliographic record

Rep Pract Oncol Radiother 2015;20(3):217-222.

Keywords

Rhabdomyosarcoma
Proton-beam therapy
Genitourinary/pelvic tumor
Childhood malignancy
Multimodal therapy

Authors

Hiroko Fukushima
Takashi Fukushima
Aiko Sakai
Ryoko Suzuki
Chie Kobayashi
Yoshiko Oshiro
Masashi Mizumoto
Noriko Hoshino
Chikashi Gotoh
Yasuhisa Urita
Hiroaki Komuro
Michio Kaneko
Noritoshi Sekido
Kouji Masumoto
Hideyuki Sakurai
Ryo Sumazaki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl